Supernus Pharmaceuticals, Inc.

Total Valuation

Supernus Pharmaceuticals, Inc. carries a market capitalization of 2.56B, placing it among publicly traded companies globally. Its enterprise value stands at 2.60B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Supernus Pharmaceuticals, Inc. currently has 58.04M shares outstanding.

Valuation Ratios

Supernus Pharmaceuticals, Inc. trades at a trailing price-to-earnings ratio of 27.18. The price-to-sales ratio is 3.79, and the price-to-book ratio stands at 5.70.

Enterprise Valuation

On an enterprise value basis, Supernus Pharmaceuticals, Inc. trades at an EV/EBITDA multiple of 45.49 and an EV/FCF ratio of 30.82. The EV/Sales ratio of 3.34 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 17.92 provides insight into valuation relative to core operating earnings.

Financial Position

Supernus Pharmaceuticals, Inc. maintains a current ratio of 1.96, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

Taxes

Stock Price Statistics

Supernus Pharmaceuticals, Inc.'s stock has gained approximately 36.73596% over the past 52 weeks. The 50-day moving average sits at 49.49, while the 200-day moving average is 48.96.

Income Statement

Over the trailing twelve months, Supernus Pharmaceuticals, Inc. generated 776.83M in revenue and converted that into -29.02M in net income, yielding earnings per share of -0.51. EBITDA reached 57.10M, while operating income came in at -40.21M.

Balance Sheet

Supernus Pharmaceuticals, Inc. holds 384.24M in cash and equivalents against 40.90M in total debt, resulting in a net debt position of -184.87M. Total book value stands at 515.64M, with working capital of 357.65M providing operational flexibility.

Cash Flow

Supernus Pharmaceuticals, Inc. produced 83.26M in operating cash flow over the past twelve months. After subtracting -1.01M in capital expenditures, free cash flow totaled 82.25M - equivalent to 1.45 per share.

Margins

Supernus Pharmaceuticals, Inc. operates with a gross margin of 89.42, reflecting its pricing power and cost economics. The operating margin of -5.18 and net profit margin of -3.74 provide insight into operational efficiency.

Dividends & Yields

Scores

Supernus Pharmaceuticals, Inc. posts an Altman Z-Score of 6.32, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.